8 Neogenomics Analyst Ratings, Earnings, Dividends and Insider Trades | $NEO | NYSE:NEO | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Neogenomics Company Profile (NYSE:NEO) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Neogenomics (NYSE:NEO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)Consensus Rating:Buy (Score: 2.80)Consensus Price Target: $6.50 (85.71% upside) Analysts' Ratings History for Neogenomics (NYSE:NEO) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/14/2014StephensInitiated CoverageOverweight$6.00View 1/8/2014William BlairInitiated CoverageOutperformView 10/23/2013ZacksReiterated RatingOutperform -> Outperform$7.00View 5/1/2013SidotiInitiated CoverageBuyView 4/25/2013Ladenburg ThalmannDowngradeBuy -> NeutralView 2/14/2013Ladenburg ThalmannBoost Price TargetBuy$3.50 -> $3.75View (Data available from 3/11/2012 forward) Earnings History for Neogenomics (NYSE:NEO)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView 10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView 7/31/2013Q2 2013$0.00$0.01$16.20 million$15.60 millionViewN/AView 2/14/2013Q4 2012($0.01)$0.00$14.72 million$14.90 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Neogenomics (NYSE:NEO)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Neogenomics (NYSE:NEO)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View 12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View 12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View 12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View 11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View 4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View (Data available from 1/1/2013 forward) About Neogenomics NeoGenomics, Inc. (NeoGenomics) operates a network of cancer-focused testing laboratories. The Company offers testing services, including Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, this is the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens, and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level. Headlines: (2/19) NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share ... (2/14) Neogenomics started Overweight at Stephens (2/19) NeoGenomics Q4 13 Earnings Conference Call At 11:00 AM ET (2/20) Five Star Equities Issues New Research Reports on AMSC, GRMN, NEO and UCTT (2/19) Sector Update: Healthcare Shares Flat Pre-Market; NeoGenomics Down 2% on Expected Impact of Billing Changes (2/19) Sector Update: Health Care (2/18) RDInvesting Provides Investors with Free In-Depth Equity Reports on CKSW, CMLS, NEO and QSII (2/19) Neogenomics Inc. EPS in-line, beats on revenue Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NYSE Symbol: NEO CUSIP: Key Metrics: Previous Close: $3.4450 Day Moving Average: $3.7391200 Day Moving Average: $3.4072 P/E Ratio: 86.00P/E Growth: 17.65Market Cap: $171.9MCurrent Quarter EPS Consensus Estimate: $0.01 EPS Additional Links: View NEO on Google FinanceView NEO on Yahoo FinanceView NEO's Company Profile on ReutersSearch for Neogenomics on Google Neogenomics (NYSE:NEO) Chart for Tuesday, March, 11, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.